RxDoctor Payments Data

Linda Harris, MD

Vascular Surgery · Buffalo, NYNPI 1053339515

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $11,514 of the $16,508 with a category attached, or 69.7%. It is spread thinly across 40 manufacturers, the largest accounting for just 23.7%. Reporting peaked in 2023 at $3,742 and has fallen 51.1% since, to $1,829 in 2025.

$16,508in general payments, 2019–2025

Across 301 payments — averaging $54.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Incorporated$4K
  • W. L. Gore & Associates, Inc.$2K
  • Medtronic$2K
  • Inari Medical, Inc.$1K
  • Cook Medical LLC$890
  • Shape Memory Medical Inc.$853
  • plus $5K from 34 others
$88,247in research payments, 2019–2025

Across 13 payments — averaging $6788.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shape Memory Medical Inc.$43K
  • W. L. Gore & Associates, Inc.$38K
  • KCI USA, Inc.$7K

What the payments were for

  • Speaking & faculty fees$2,55015%
  • Grants$2,35014%
  • Travel & lodging$851%
  • Food & beverage$11,51470%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,508 in reported general payments places this provider in the 75th percentile of 405 vascular surgery providers in New York.

See all vascular surgery providers in New York

Medicare billing

Part B allowed, 2024
$116,335
Medicare patients
523
Services billed
1,284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban17$21,082
Cilostazol110$2,965
Pentoxifylline31$780
ClopidogrelClopidogrel Bisulfate47$719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$615$21,08217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 405 vascular surgery providers in New York.

Other vascular surgery in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →